Transition Therapeutics sees positive initial data on E1-I.N.T. for diabetes

New York, Dec. 5 - Transition Therapeutics Inc. said that initial results from its ongoing phase 2a clinical trial of E1-I.N.T. for diabetes showed a reduction in daytime insulin usage and a favorable safety profile when the therapy was titrated to maximal doses.

The announcement is based on preliminary data from the first four type I diabetes patients to complete the four-week treatment period using either E1-I.N.T. or a placebo.

"Although preliminary and blinded, these interim data show diabetes patients tolerating escalating doses of E1-I.N.T. treatment and three of four type I diabetes patients reducing their daytime insulin usage by 35%-75%." said Sherwyn Schwartz, director of Diabetes and Glandular Disease Research Associates in San Antonio, in a news release. Schwartz enrolled these first patients in the study.

E1-I.N.T. is being evaluated in an ongoing exploratory phase 2a clinical study for type I and type II diabetes patients as well as blinded safety and efficacy data for the type I diabetes clinical study. The main objective is to identify well-tolerated and safe doses and signs of efficacy by measuring parameters including insulin usage and HbA1c levels.

E1-I.N.T. is a short course combination therapy aimed at stimulating the regeneration of islet cells, which produce insulin.

Eventually, the phase 2a trial will examine 20 type I diabetes patients and 30 type II diabetes patients. Final results are expected in the middle of 2006.

Transition Therapeutics is a Toronto-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.